Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV

Abstract

Four years of cyclical intravenous pamidronate treatment led to a significant height gain in moderately to severely affected OI patients.